Carregant...

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

Rapid development of the small molecule proteasome inhibitor bortezomib has yielded important clinical benefit for patients with multiple myeloma. Early phase clinical trials suggest the agent has similar efficacy in Waldenströms Macroglobulinemia. Optimization of bortezomib-based therapy, though, r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: LAUBACH, JACOB P., MITSIADES, CONSTANTINE S., ROCCARO, ALDO M., GHOBRIAL, IRENE M., ANDERSON, KENNETH C., RICHARDSON, PAUL G.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3133638/
https://ncbi.nlm.nih.gov/pubmed/19452315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190902866732
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!